COP vs CORT · P/E 19, rev $58.94B vs P/E 199, rev $675.0M
ConocoPhillips (COP) versus Corcept Therapeutics Incorporated (CORT) — a side-by-side from cached financials, not a winner call.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Corcept Therapeutics Incorporated (CORT) is a biotechnology company listed on US.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Latest reported CORT revenue for 2024-12-31 was $675.0M. Net income was $141.2M. Revenue was up 39.9% from 2023-12-31 to 2024-12-31. CORT currently screens at market cap $7.46B and trailing P/E 198.5.
COP currently screens at market cap $135.49B and trailing P/E 18.8. CORT currently screens at market cap $7.46B and trailing P/E 198.5.
Not investment advice. Open the COP and CORT stock pages for the full models.
Not investment advice.